Steady-state pharmacokinetics of metronidazole in Crohn's disease.
The pharmacokinetics of metronidazole (MTZ) were studied in six Crohn's disease patients after multiple oral daily doses of 250, 500, 750, and 1000 mg day-1. Pharmacokinetic indices were found to be independent of the dose administered. The half-life, volume of distribution and oral clearance of metronidazole were 9.5 +/- 2.1 h, 0.732 +/- 0.094 l kg-1 and 0.921 +/- 0.175 (ml min-1) kg-1 (mean +/- SD), respectively. A strong linear correlation (r = 0.95) was found between the volume of distribution of MTZ and the patients' total body weight. The percentage of dose of metronidazole excreted in urine as the intact drug and metabolites as well as glucuronic acid conjugates ranged from 34.7 +/- 7.4 to 58.9 +/- 5.2. Both plasma and urine data exhibited very large inter-patient variations. However, intra-patient variations were negligible. Strong positive linear correlations were observed between the dose and the areas under the plasma concentration versus time curves, peak plasma concentrations as well as cumulative urinary excretion of the drug and its metabolites. It is concluded that in Crohn's disease, the pharmacokinetics of MTZ and its metabolites are linear and that the drug concentrations are dependent on the total body weight.
D000328:Adult; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D003424:Crohn Disease / Q000378:metabolism*; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D008795:Metronidazole / Q000031:analogs & derivatives / Q000378:metabolism* / Q000652:urine; D008875:Middle Aged
D005965:Glucuronates; D008795:Metronidazole; C020910:1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole; C020921:2-methyl-5-nitroimidazol-1-ylacetic acid